Reduced incidence of upper gastrointestinal ulcer complications with the COX‐2 selective inhibitor, valdecoxib

Valdecoxib, including above recommended doses, is associated with a significantly lower rate of upper gastrointestinal ulcer complications than therapeutic doses of non-selective non-steroidal anti-inflammatory drugs.